Community Behavioral Health: Provider Notification
Updated Long-Acting Injectables (LAI) Toolkit
February 5, 2019

Long-acting injectables (LAI) have been shown through research to 1) improve medication adherence, 2) reduce frequency of symptom relapse, 3) reduce re-hospitalization, and 4) improve treatment outcomes for individuals who struggle with adherence to antipsychotic medication. Despite this evidence, LAIs remain an underutilized option for individuals receiving mental health treatment. To ease access to LAIs and related supports for individuals prescribed antipsychotics, and to facilitate seamless transitions for individuals from inpatient to community settings, CBH previously published the LAI Provider Toolkit. The Toolkit has been updated to include new medication information and formulary changes since its original release in 2017. The Toolkit can be found on the CBH website here [https://cbhphilly.org/cbh-providers/long-acting-injectable-toolkit/](https://cbhphilly.org/cbh-providers/long-acting-injectable-toolkit/) and currently includes:

- LAI Toolkit Fact Sheet
- LAI Referral Flow
- LAI Toolkit Webinar
- MCO and Pharmacy Benefit Crosswalk
- List of CBH in-network Outpatient and CIRC providers who administer LAIs
- Case Management Application
- Prior Authorization Forms
  - Aetna Generic Prior Auth
  - Aetna LAI-Antipsychotics
  - HPP Abilify Maintena PA
  - HPP Invega-Sustenna PA
  - HPP Invega-Trinza PA
  - HPP Risperdal-Consta PA
  - Keystone First LAI PA
  - United Atypical Antipsychotic PA

Please direct any questions related to LAIs or the Toolkit to Jeffrey Sensenig at jeffrey.sensenig@phila.gov or 267-602-2073.